Literature DB >> 10755070

Synaptophysin gene expression in schizophrenia. Investigation of synaptic pathology in the cerebral cortex.

S L Eastwood1, N J Cairns, P J Harrison.   

Abstract

BACKGROUND: Decreased expression of proteins such as synaptophysin in the hippocampus and prefrontal cortex in schizophrenia is suggestive of synaptic pathology. However, the overall profile of changes is unclear. AIMS: To investigate synaptophysin gene expression in the cerebral cortex in schizophrenia.
METHOD: The dorsolateral prefrontal (Brodmann area [BA] 9/46), anterior cingulate (BA 24), superior temporal (BA 22) and occipital (BA 17) cortex were studied in two series of brains, totalling 19 cases and 19 controls. Synaptophysin was measured by immunoautoradiography and immunoblotting. Synaptophysin messenger RNA (mRNA) was measured using in situ hybridisation.
RESULTS: Synaptophysin was unchanged in schizophrenia, except for a reduction in BA 17 of one brain series. Synaptophysin mRNA was decreased in BA 17, and in BA 22 in the women with schizophrenia. No alterations were seen in BA 9/46.
CONCLUSIONS: Synaptophysin expression is decreased in some cortical areas in schizophrenia. The alterations affect the mRNA more than the protein, and have an unexpected regional distribution. The characteristics of the implied synaptic pathology remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10755070     DOI: 10.1192/bjp.176.3.236

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  23 in total

Review 1.  Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia.

Authors:  C Konradi; S Heckers
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 2.  Understanding the pathology of schizophrenia: recent advances from the study of the molecular architecture of postmortem CNS tissue.

Authors:  B Dean
Journal:  Postgrad Med J       Date:  2002-03       Impact factor: 2.401

Review 3.  The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications.

Authors:  Paul J Harrison
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

Review 4.  Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.

Authors:  Ying C Li; Ege T Kavalali
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

Review 5.  Glutamate dysfunction in hippocampus: relevance of dentate gyrus and CA3 signaling.

Authors:  Carol A Tamminga; Sarah Southcott; Carolyn Sacco; Anthony D Wagner; Subroto Ghose
Journal:  Schizophr Bull       Date:  2012-04-24       Impact factor: 9.306

6.  Lasting changes induced by mild alcohol exposure during embryonic development in BDNF, NCAM and synaptophysin-positive neurons quantified in adult zebrafish.

Authors:  Samantha Mahabir; Dipashree Chatterjee; Keith Misquitta; Diptendu Chatterjee; Robert Gerlai
Journal:  Eur J Neurosci       Date:  2018-06-15       Impact factor: 3.386

Review 7.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

8.  SNAP-25a/b Isoform Levels in Human Brain Dorsolateral Prefrontal Cortex and Anterior Cingulate Cortex.

Authors:  Peter M Thompson; Dianne A Cruz; Elizabeth A Fucich; Dianna Y Olukotun; Masami Takahashi; Makoto Itakura
Journal:  Mol Neuropsychiatry       Date:  2015-12-01

9.  Cortical blood flow during rest and Wisconsin Card Sorting Test performance in schizophrenia.

Authors:  Felipe Ortuño; Miguel Moreno-Iñiguez; Manuel Millán; César A Soutullo; Raphael M Bonelli
Journal:  Wien Med Wochenschr       Date:  2006-04

10.  Perinatal oxygen restriction does not result in reduced rat frontal cortex synaptophysin protein levels at adulthood as opposed to postmortem findings in schizophrenia.

Authors:  Carmit Nadri; Galila Agam
Journal:  J Mol Neurosci       Date:  2008-07-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.